Covid-19
COVID longa: visando a um consenso.
10 Mai, 2022 | 12:38hLong COVID: aiming for a consensus – The Lancet Respiratory Medicine
Comentário no Twitter
There is an urgent need for unification of terminology for the sequelae of #SARSCoV2 infection to ensure that research is directed towards and translated into interventional trials to improve outcomes
NEW Comment—#LongCOVID: aiming for a consensushttps://t.co/dZO4rBVCSY pic.twitter.com/H5ezqL0RLb
— The Lancet Respiratory Medicine (@LancetRespirMed) May 5, 2022
Revisão | Patogênese do SARS-CoV-2.
10 Mai, 2022 | 12:37hSARS-CoV-2 pathogenesis – Nature Reviews Microbiology
Comentário no Twitter
A Review published in @NatureRevMicro explores recent clinical and experimental advances in understanding SARS-CoV-2 pathogenesis, interactions with host cells and the involvement of the immune system in the development of severe disease. https://t.co/GTm0BZ3ikH pic.twitter.com/jPXFU05Pwm
— Nature Portfolio (@NaturePortfolio) April 23, 2022
Estudo de efetividade comparativa | Oxigenação extracorpórea venovenosa em pacientes com insuficiência respiratória associada a Covid-19 aguda.
6 Mai, 2022 | 17:42h
Comentário no Twitter
In this international, registry based cohort study of patients with covid-19 associated acute respiratory failure, extracorporeal membrane oxygenation was associated with a reduction in mortality by 7.1% compared with conventional mechanical ventilation https://t.co/VkNFeRDQ3j
— The BMJ (@bmj_latest) May 4, 2022
M-A | Eficácia e efetividade das vacinas contra SARS-CoV-2.
6 Mai, 2022 | 17:36hEfficacy and Effectiveness of SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis – Vaccines
Falha do Paxlovid como medida preventiva levanta questionamentos, mas os médicos ainda o consideram como um tratamento.
6 Mai, 2022 | 16:58hRemdesivir e 3 outros medicamentos para pacientes internados com COVID-19: resultados finais do estudo randomizado WHO Solidarity e metanálise atualizada.
4 Mai, 2022 | 14:07hComentário convidado: When and which patients should receive remdesivir? – The Lancet
Estudos randomizados | Efeitos de um programa online de respiração e bem-estar para pessoas com sintomas persistentes após COVID-19.
4 Mai, 2022 | 14:05hComentário convidado: Treating COVID-19-related breathlessness with novel interventions – The Lancet Respiratory Medicine
Comunicado de imprensa: Singing techniques can improve quality of life and breathlessness after COVID-19 – Imperial College London
Comentário no Twitter
NEW Research—Online breathing and wellbeing programme (ENO Breathe) can improve mental
component of HRQoL & elements of breathlessness in #LongCovidStudy from @keirphilip, @COPDdoc, & colleagues https://t.co/Sn0TO6gSev pic.twitter.com/asTiepHhyz
— The Lancet Respiratory Medicine (@LancetRespirMed) April 28, 2022
Revisão sistemática | Telerreabilitação melhora a função física e reduz a dispneia em pessoas com COVID-19 e condições pós-COVID-19.
4 Mai, 2022 | 14:03hPonto/Contraponto | Heparina terapêutica deveria ser administrada para pacientes críticos internados com COVID-19?
4 Mai, 2022 | 14:00hCONTRPONTO: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? No – CHEST
Ver também: Rebuttal From Dr Tritschler et al – CHEST
Conteúdos relacionados:
Anticoagulants for people hospitalised with COVID‐19 – Cochrane Library
Pfizer afirma que o tratamento de COVID com Paxlovid não previne infecção domiciliar.
3 Mai, 2022 | 16:46hPfizer says COVID treatment Paxlovid fails to prevent infection of household members – Reuters
Comentário no Twitter
Pfizer Inc on Friday said a large trial found that its COVID-19 oral antiviral treatment Paxlovid was not effective at preventing coronavirus infection in people living with someone who had been exposed to the virus. https://t.co/95zphEYaxc
— Reuters Health (@Reuters_Health) April 29, 2022